The global HIV diagnostics test market is witnessing significant growth in demand for rapid HIV diagnostics tests to support early detection and treatment of HIV infection. Rapid HIV diagnostics tests provide accurate results within 20-30 minutes and enable onsite counseling and care. The increasing awareness regarding early detection and benefits of antiretroviral treatment (ART) is further supporting the adoption of rapid tests in counselling and testing centers.

HIV diagnostics tests help detect the presence of HIV, the virus that causes AIDS, in the body. Key products used in HIV testing include rapid diagnostic tests, western blot tests, immunofluorescence assays, nucleic acid tests, and clinical testing. Rapid diagnostic tests are miniaturized tests that can be performed at the point-of-care to detect antibodies and antigens with high accuracy. They reduce turnaround time by offering onsite results and support effective linking of those who test positive to treatment programs and pre-exposure prophylaxis. This helps curb new infections and improves health outcomes. Growing access to testing and treatment in developing regions is a key driver.

The Global HIV diagnostics test market is estimated to be valued at US$ 4,263.62 mn in 2024 and is expected to exhibit a CAGR of 9.0% over the forecast period 2023 to 2030.

Key Takeaways
Key players operating in the HIV diagnostics test are Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd. These players are focusing on developing rapid HIV diagnostic tests and molecular assays to strengthen their market position.

The growing demand for point-of-care testing and rapid result HIV tests is a major factor boosting the market growth. Rapid HIV diagnostic tests have significantly increased testing rates by providing prompt results. These onsite tests have improved treatment linkage and access to care. The rising availability of low-cost rapid HIV tests especially in developing countries is supporting market expansion.

Market Trends
Increasing adoption of self-testing: The approval and implementation of over-the-counter HIV self-testing kits without a medical practitioner's supervision is simplifying testing. This helps address barriers of privacy, cost and stigma and supports more frequent screening.

Market Opportunities
Integration of HIV monitoring with other infectious disease testing: Opportunities lie in developing combo diagnostic panels integrating HIV diagnostics with testing for co-infections such as tuberculosis, hepatitis, HPV, to facilitate comprehensive disease management.

Fastest Growing Geographical Region
The Asia Pacific region has emerged as the fastest growing market for HIV diagnostics globally since the pandemic. While India and China capture highest number of people living with HIV, other Association of Southeast Asian Nations (ASEAN) countries like Vietnam and Philippines are also reporting increasing infection rates each year. With improving access to healthcare through initiatives like the National AIDS Control Programme, regular diagnostic testing is on the rise. Additionally, presence of emerging economies offering opportunities for development of affordable rapid testing technologies is attracting major players to strengthen their foothold in the region. This is expected to drive Asia Pacific market at a high CAGR through 2030.